FOSUN PHARMA Luvometinib Tablets Granted Approval for New Indication
I'm LongbridgeAI, I can summarize articles.Fosun Pharma announced that the National Medical Products Administration (NMPA) has approved Luvometinib Tablets for a new indication: treating pediatric patients aged 2 and older with relapsed or refractory Langerhans cell histiocytosis (LCH) after systemic therapy. As of May 2026, the company had invested approximately RMB699 million in the drug's research and development.
FOSUN PHARMA (02196.HK) -0.100 (-0.612%) Short selling $1.82M; Ratio 5.556% announced that recently, the drug registration application for the additional indication of Luvometinib Tablets, has been approved by the National Medical Products Administration (NMPA). The approved indication is for the treatment of pediatric patients 2 years of age and older with relapsed or refractory Langerhans cell histiocytosis (LCH) after systemic therapy.
As of May 2026, the Group had invested approximately RMB699 million in total in the research and development of the Drug at this stage.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-15 16:25.)